Presence of anti-TIF-1γ, anti-Ro52, anti-SSA/Ro60 and anti-Su/Ago2 antibodies in breast cancer: a cross-sectional study

References

• Zaenker P, Gray ES, Ziman MR. Autoantibody production in cancer-the humoral immune response toward autologous antigens in cancer patients. Autoimmun Rev. 2016;15(5):477–483.
   PubMed Web of Science ®Google Scholar
• Bei R, Masuelli L, Palumbo C, et al. A common repertoire of autoantibodies is shared by cancer and autoimmune disease patients: inflammation in their induction and impact on tumor growth. Cancer Lett. 2009;281(1):8–23.
   PubMed Web of Science ®Google Scholar
• Silva ML. Cancer serum biomarkers based on aberrant post-translational modifications of glycoproteins: clinical value and discovery strategies. Biochim Biophys Acta. 2015;1856(2):165–177.
   PubMed Web of Science ®Google Scholar
• Venalis P, Selickaja S, Lundberg K, et al. Association of anti-transcription intermediary factor 1gamma antibodies with paraneoplastic rheumatic syndromes other than dermatomyositis. Arthritis Care Res. 2018;70(4):648–651. (Hoboken).
   Web of Science ®Google Scholar
• Pantazopoulou VI, Georgiou S, Kakoulidis P, et al. From the argonauts mythological sailors to the argonautes RNA-silencing navigators: their emerging roles in human-cell pathologies. Int J Mol Sci. 2020;21(11):4007.
   Web of Science ®Google Scholar
• Satoh M, Chan JY, Ceribelli A, et al. Autoantibodies to argonaute 2 (Su antigen). Adv Exp Med Biol. 2013;768:45–59.
   PubMed Web of Science ®Google Scholar
• Palafox Sanchez CA, Satoh M, Chan EK, et al. Reduced IgG anti-small nuclear ribonucleoprotein autoantibody production in systemic lupus erythematosus patients with positive IgM anti-cytomegalovirus antibodies. Arthritis Res Ther. 2009;11(1):R27.
   PubMed Web of Science ®Google Scholar
• Bacon JL. The menopausal transition. Obstet Gynecol Clin North Am. 2017;44(2):285–296.
   PubMed Web of Science ®Google Scholar
• Seshie B, Adu-Aryee NA, Dedey F, et al. A retrospective analysis of breast cancer subtype based on ER/PR and HER2 status in Ghanaian patients at the Korle Bu Teaching Hospital, Ghana. BMC Clin Pathol. 2015;15:14.
   PubMed Web of Science ®Google Scholar
• Blows FM, Driver KE, Schmidt MK, et al. Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies. PLOS Med. 2010;7(5):e1000279.
   PubMed Web of Science ®Google Scholar
• Bandala C, De la Garza-Montano P, Cortes-Algara A, et al. Association of histopathological markers with clinico-pathological factors in Mexican women with breast cancer. Asian Pac J Cancer Prev. 2016;16(18):8397–8403.
   Google Scholar
• Satoh M, Langdon JJ, Chou CH, et al. Characterization of the Su antigen, a macromolecular complex of 100/102 and 200-kDa proteins recognized by autoantibodies in systemic rheumatic diseases. Clin Immunol Immunopathol. 1994;73(1):132–141.
   PubMedGoogle Scholar
• Petri MH, Satoh M, Martin-Marquez BT, et al. Implications in the difference of anti-Mi-2 and -p155/140 autoantibody prevalence in two dermatomyositis cohorts from Mexico City and Guadalajara. Arthritis Res Ther. 2013;15(2):R48.
   PubMed Web of Science ®Google Scholar
• Tan EM, Zhang J. Autoantibodies to tumor-associated antigens: reporters from the immune system. Immunol Rev. 2008;222:328–340.
   PubMed Web of Science ®Google Scholar
• Criscitiello C. Tumor-associated antigens in breast cancer. Breast Care. 2012;7(4):262–266.
   PubMed Web of Science ®Google Scholar
• McKeown E, Nelson DW, Johnson EK, et al. Current approaches and challenges for monitoring treatment response in colon and rectal cancer. J Cancer. 2014;5(1):31–43.
   PubMed Web of Science ®Google Scholar
• Zhang J, Xu Z, Yu L, et al. Assessment of the potential diagnostic value of serum p53 antibody for cancer: a meta-analysis. PLOS One. 2014;9(6):e99255.
   PubMed Web of Science ®Google Scholar
• Le May M, Dent S. Anti-Yo antibody-mediated paraneoplastic cerebellar degeneration associated with cognitive affective syndrome in a patient with breast cancer: a case report and literature review. Curr Oncol. 2018;25(6):e585–e591.
   PubMed Web of Science ®Google Scholar
• Kannoth S. Paraneoplastic neurologic syndrome: a practical approach. Ann Indian Acad Neurol. 2012;15(1):6–12.
   PubMed Web of Science ®Google Scholar
• Giat E, Ehrenfeld M, Shoenfeld Y. Cancer and autoimmune diseases. Autoimmun Rev. 2017;16(10):1049–1057.
   PubMed Web of Science ®Google Scholar
• Fattet L, Ay AS, Bonneau B, et al. TIF1γ requires sumoylation to exert its repressive activity on TGFβ signaling. J Cell Sci. 2013;126(Pt 16):3713–3723.
   PubMed Web of Science ®Google Scholar
• Hesling C, Lopez J, Fattet L, et al. Tif1γ is essential for the terminal differentiation of mammary alveolar epithelial cells and for lactation through SMAD4 inhibition. Development. 2013;140(1):167–175.
   PubMed Web of Science ®Google Scholar
• Hachim MY, Hachim IY, Dai M, et al. Differential expression of TGFβ isoforms in breast cancer highlights different roles during breast cancer progression. Tumour Biol. 2018;40(1):1010428317748254.
   Google Scholar
• Fiorentino DF, Chung LS, Christopher-Stine L, et al. Most patients with cancer-associated dermatomyositis have antibodies to nuclear matrix protein NXP-2 or transcription intermediary factor 1γ. Arthritis Rheum. 2013;65(11):2954–2962.
   PubMed Web of Science ®Google Scholar
• Masiak A, Kulczycka J, Czuszyńska Z, et al. Clinical characteristics of patients with anti-TIF1-γ antibodies. Reumatologia. 2016;54(1):14–18.
   PubMedGoogle Scholar
• Kubecek O, Soukup T, Paulik A, et al. Dermatomyositis with anti-TIF-1γ antibodies as a presenting symptom of underlying triple-negative breast cancer: a case report. BMC Cancer. 2016;16(1):684.
   PubMedGoogle Scholar
• Infantino M, Meacci F, Grossi V, et al. Serological epitope profile of anti-Ro52-positive patients with systemic autoimmune rheumatic diseases. Arthritis Res Ther. 2015;17:365.
   PubMed Web of Science ®Google Scholar
• Menor Almagro R, Jurado Roger A, Rodríguez Gutiérrez FJ, et al. Association of anti-Ro52, anti-Ro60 and anti-La antibodies with diagnostic, clinical and laboratory features in a referral hospital in Jerez. Spain. Reumatol Clin. 2016;12(5):256–262.
   PubMed Web of Science ®Google Scholar
• Kuboshima M, Shimada H, Liu TL, et al. Presence of serum tripartite motif-containing 21 antibodies in patients with esophageal squamous cell carcinoma. Cancer Sci. 2006;97(5):380–386.
   PubMed Web of Science ®Google Scholar
• Menendez A, Gomez J, Escanlar E, et al. Clinical associations of anti-SSA/Ro60 and anti-Ro52/TRIM21 antibodies: diagnostic utility of their separate detection. Autoimmunity. 2013;46(1):32–39.
   PubMed Web of Science ®Google Scholar
• Zou HY, Gu X, Yu WZ, et al. Detection of serum antinuclear antibodies in lymphoma patients. Genet Mol Res. 2015;14(4):16546–16552.
   PubMed Web of Science ®Google Scholar
• Espinosa A, Dardalhon V, Brauner S, et al. Loss of the lupus autoantigen Ro52/Trim21 induces tissue inflammation and systemic autoimmunity by disregulating the IL-23-Th17 pathway. J Exp Med. 2009 Aug 3;206(8):1661–1671.
   PubMed Web of Science ®Google Scholar
• Espinosa A, Zhou W, Ek M, et al. The Sjogren's syndrome-associated autoantigen Ro52 is an E3 ligase that regulates proliferation and cell death. J Immunol. 2006;176(10):6277–6285.
   PubMed Web of Science ®Google Scholar
• Zhou W, Zhang Y, Zhong C, et al. Decreased expression of TRIM21 indicates unfavorable outcome and promotes cell growth in breast cancer. Cancer Manag Res. 2018;10:3687–3696.
   PubMed Web of Science ®Google Scholar
• Ding Q, He D, He K, et al. Downregulation of TRIM21 contributes to hepatocellular carcinoma carcinogenesis and indicates poor prognosis of cancers. Tumour Biol. 2015;36(11):8761–8772.
   PubMedGoogle Scholar
• Brauner S, Zhou W, Backlin C, et al. Reduced expression of TRIM21/Ro52 predicts poor prognosis in diffuse large B-cell lymphoma patients with and without rheumatic disease. J Intern Med. 2015;278(3):323–332.
   PubMed Web of Science ®Google Scholar
• Itou J, Li W, Ito S, et al. Sal-like 4 protein levels in breast cancer cells are post-translationally down-regulated by tripartite motif-containing 21. J Biol Chem. 2018;293(17):6556–6564.
   PubMed Web of Science ®Google Scholar
• Ohlsson M, Jonsson R, Brokstad KA. Subcellular redistribution and surface exposure of the Ro52, Ro60 and La48 autoantigens during apoptosis in human ductal epithelial cells: a possible mechanism in the pathogenesis of Sjögren's syndrome. Scand J Immunol. 2002;56(5):456–469.
   PubMed Web of Science ®Google Scholar
• Ye Z, Jin H, Qian Q. Argonaute 2: a novel rising star in cancer research. J Cancer. 2015;6(9):877–882.
   PubMed Web of Science ®Google Scholar
• Adams BD, Kasinski AL, Slack FJ. Aberrant regulation and function of microRNAs in cancer. Curr Biol. 2014;24(16):R762–76.
   PubMed Web of Science ®Google Scholar